Dechra Pharmaceuticals said trading in the period from the start of July to the end of December was strong and in line with management expectations.
Reported group revenue increased by around 10.5% at constant exchange rates and at around 11.5% at actual exchange rates.
It said European pharmaceuticals revenue growth was around 5.5% at CER (AER c.8.5%) and North America pharmaceuticals revenue growth was c.20.0% at CER (AER c.17.5%).
The group also completed the small bolt on acquisition of RxVet Limited, New Zealand.
At 8:20am: (LON:DPH) Dechra Pharmaceuticals PLC share price was +62p at 2068p